Back to Authors

Wadley, Virginia G.

https://orcid.org/0000-0003-4524-8395

Mayo Clinic

University of Alabama at Birmingham

Citations 5

Baseline cognitive function among participants in the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (Crest-2) (S50.007)
Lazar, Ronald M. , Wadley, Virginia G. , Voeks, Jenifer H. , Yuan, Ya , Lal, Brajesh K. , Heck, Donald , Jones, Michael , Brott, Thomas G. , Marshall, Randolph S. , Howard, George , Howard, Virginia J. , Meschia, James F.

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s50.007 Get It

CENTRALIZED COGNITIVE ASSESSMENT IN A MULTICENTER TRIAL OF TREATMENT MODES FOR ASYMPTOMATIC CAROTID ARTERY DISEASE
Wadley, Virginia G. , Lal, Brajesh K. , Brott, Thomas G. , Lazar, Ronald M. , Howard, Virginia J. , Knopman, David S. , Meschia, James F. , Howard, George

Innovation in Aging | November 10, 2018 | Volume: 2 | Issue: suppl_1 | Pages: 702-702

10.1093/geroni/igy023.2607 Get It

Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials
Howard, Virginia J. , Lal, Brajesh K. , Turan, Tanya N. , Roubin, Gary S., Brown, Robert D. , Voeks, Jenifer H. , Barrett, Kevin M. , Lazar, Ronald M. , Moore, Wesley S. , Wadley, Virginia G. , Moy, Claudia S., Chimowitz, Marc I. , Howard, George , Brott, Thomas G. , Meschia, James F. , Demaerschalk, Bart M. , Huston, John , Chaturvedi, Seemant , Howard, Virginia J , Howard, George

International Journal of Stroke | May 2, 2017 | Volume: 12 | Issue: 7 | Pages: 770-778

10.1177/1747493017706238 Get It

Rationale Trials conducted decades ago demonstrated that carotid endarterectomy by skilled surgeons reduced stroke risk in asymptomatic patients. Developments in carotid stenting and improvements in medical prevention of stroke caused by atherothrombotic disease challenge understanding of the benefits of revascularization. Aim Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) will test whether carotid endarterectomy or carotid stenting plus contemporary intensive medical therapy is superior to intensive medical therapy alone in the primary prevention of stroke in patients with high-grade asymptomatic carotid stenosis. Methods and design CREST-2 is two multicenter randomized trials of revascularization plus intensive medical therapy versus intensive medical therapy alone. One trial randomizes patients to carotid endarterectomy plus intensive medical therapy versus intensive medical therapy alone; the other, to carotid stenting plus intensive medical therapy versus intensive medical therapy alone. The risk factor targets of centrally directed intensive medical therapy are LDL cholesterol <70 mg/dl and systolic blood pressure <140 mmHg. Study outcomes The primary outcome is the composite of stroke and death within 44 days following randomization and stroke ipsilateral to the target vessel thereafter, up to four years. Change in cognition and differences in major and minor stroke are secondary outcomes. Sample size Enrollment of 1240 patients in each trial provides 85% power to detect a treatment difference if the event rate in the intensive medical therapy alone arm is 4.8% higher or 2.8% lower than an anticipated 3.6% rate in the revascularization arm. Discussion Management of asymptomatic carotid stenosis requires contemporary randomized trials to address whether carotid endarterectomy or carotid stenting plus intensive medical therapy is superior in preventing stroke beyond intensive medical therapy alone. Whether carotid endarterectomy or carotid stenting has favorable effects on cognition will also be tested. Trial registration United States National Institutes of Health Clinicaltrials.gov NCT02089217